Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 5Terminated 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × ZD4054 × Genitourinary × Clear all
NCT01119118 2019-11-21

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

University of Wisconsin, Madison

Phase 2 Terminated
6 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01000948 2014-01-08

DAPROCA-1

Aarhus University Hospital

Phase 2 Terminated
24 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00626548 2012-09-03

ENTHUSE M0

AstraZeneca

Phase 3 Terminated
2,577 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡